Cargando…

Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells

In the context of tumorigenesis, telomere shortening is associated with apparent antagonistic outcomes: On one side, it favors cancer initiation through mechanisms involving genome instability, while on the other side, it prevents cancer progression, due to the activation of the DNA damage response...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherfils‐Vicini, Julien, Gilson, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609909/
https://www.ncbi.nlm.nih.gov/pubmed/31273935
http://dx.doi.org/10.15252/emmm.201910845
_version_ 1783432406584262656
author Cherfils‐Vicini, Julien
Gilson, Eric
author_facet Cherfils‐Vicini, Julien
Gilson, Eric
author_sort Cherfils‐Vicini, Julien
collection PubMed
description In the context of tumorigenesis, telomere shortening is associated with apparent antagonistic outcomes: On one side, it favors cancer initiation through mechanisms involving genome instability, while on the other side, it prevents cancer progression, due to the activation of the DNA damage response (DDR) checkpoint behaving as a cell‐intrinsic proliferation barrier. Consequently, telomerase, which can compensate for replicative erosion by adding telomeric DNA repeats at the chromosomal DNA extremities, is crucial for cancer progression and is upregulated in nearly 90% of human cancers. Therefore, telomeres are considered potential anti‐cancer targets and, to date, most of the studies have focused on telomerase inhibition. However, the development of clinically efficient telomerase targeting therapies is still in its infancy. In this context, the findings reported in this issue of EMBO Molecular Medicine by Bejarano et al (2019) open new avenues for alternative telomere therapies.
format Online
Article
Text
id pubmed-6609909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66099092019-07-15 Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells Cherfils‐Vicini, Julien Gilson, Eric EMBO Mol Med News & Views In the context of tumorigenesis, telomere shortening is associated with apparent antagonistic outcomes: On one side, it favors cancer initiation through mechanisms involving genome instability, while on the other side, it prevents cancer progression, due to the activation of the DNA damage response (DDR) checkpoint behaving as a cell‐intrinsic proliferation barrier. Consequently, telomerase, which can compensate for replicative erosion by adding telomeric DNA repeats at the chromosomal DNA extremities, is crucial for cancer progression and is upregulated in nearly 90% of human cancers. Therefore, telomeres are considered potential anti‐cancer targets and, to date, most of the studies have focused on telomerase inhibition. However, the development of clinically efficient telomerase targeting therapies is still in its infancy. In this context, the findings reported in this issue of EMBO Molecular Medicine by Bejarano et al (2019) open new avenues for alternative telomere therapies. John Wiley and Sons Inc. 2019-06-13 2019-07 /pmc/articles/PMC6609909/ /pubmed/31273935 http://dx.doi.org/10.15252/emmm.201910845 Text en © 2019 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Cherfils‐Vicini, Julien
Gilson, Eric
Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title_full Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title_fullStr Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title_full_unstemmed Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title_short Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
title_sort inhibiting trf1 upstream signaling pathways to target telomeres in cancer cells
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609909/
https://www.ncbi.nlm.nih.gov/pubmed/31273935
http://dx.doi.org/10.15252/emmm.201910845
work_keys_str_mv AT cherfilsvicinijulien inhibitingtrf1upstreamsignalingpathwaystotargettelomeresincancercells
AT gilsoneric inhibitingtrf1upstreamsignalingpathwaystotargettelomeresincancercells